glp 1 agonist trials Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Receptor Agonists as Treatments

It has been shown to be safe and well-tolerated in children and young adults, with some research documenting significant behavioral improvements

0.2 mL delivers the 3 mg target

Per FDA guidance, GLP-1-based medications are generally approved for adults with a BMI over 30, or over 27 with a qualifying health condition such as type 2 diabetes, high blood pressure, or high cholesterol

Seth Kipnis, medical director of bariatric and robotic surgery at Hackensack Meridian Jersey Shore University Medical Center, noted that there have been "rare and unusual side effects" from this class of medications, but he believes the vision changes seem to be more related to the rapid blood sugar changes caused by the medications than to the medications themselves